Toward an evolutionary containment of evolving pathogen-receptors by using an ensemble of multiple mutant ligands: from the viewpoint of fitness landscape in sequence space.

[1]  Jason T. Stevens,et al.  Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation , 2011, Nature.

[2]  Cheng Luo,et al.  How does influenza virus a escape from amantadine? , 2010, The journal of physical chemistry. B.

[3]  David Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[4]  Yuzuru Husimi,et al.  Toward the fast blind docking of a peptide to a target protein by using a four-body statistical pseudo-potential , 2010, Comput. Biol. Chem..

[5]  S. Locarnini,et al.  Molecular genesis of drug-resistant and vaccine-escape HBV mutants. , 2010, Antiviral therapy.

[6]  Philip A. Romero,et al.  Exploring protein fitness landscapes by directed evolution , 2009, Nature Reviews Molecular Cell Biology.

[7]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..

[8]  Yoko Takahashi,et al.  Development of systemic in vitro evolution and its application to generation of peptide-aptamer-based inhibitors of cathepsin E. , 2009, Journal of molecular biology.

[9]  B. Tidor,et al.  Novel Method for Probing the Specificity Binding Profile of Ligands: Applications to HIV Protease , 2008, Chemical biology & drug design.

[10]  Bernd Groner,et al.  Peptide aptamer libraries. , 2008, Combinatorial chemistry & high throughput screening.

[11]  S. Young,et al.  HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells , 2007, Proceedings of the National Academy of Sciences.

[12]  Philip A. Romero,et al.  Neutral genetic drift can alter promiscuous protein functions, potentially aiding functional evolution , 2007, Biology Direct.

[13]  Jay D Keasling,et al.  Pathway engineering by designed divergent evolution. , 2007, Current opinion in chemical biology.

[14]  T. Shibata,et al.  An ex vivo method for rapid generation of monoclonal antibodies (ADLib system) , 2006, Nature Protocols.

[15]  Jung-Hsin Lin,et al.  Optimization and Computational Evaluation of a Series of Potential Active Site Inhibitors of the V82F/I84V Drug‐resistant Mutant of HIV‐1 Protease: an Application of the Relaxed Complex Method of Structure‐based Drug Design , 2006, Chemical biology & drug design.

[16]  E. Freire,et al.  Adaptive inhibitors of the HIV-1 protease. , 2005, Progress in biophysics and molecular biology.

[17]  Alexander Tropsha,et al.  Development of a four-body statistical pseudo-potential to discriminate native from non-native protein conformations , 2003, Bioinform..

[18]  E. Freire,et al.  Designing drugs against heterogeneous targets , 2002, Nature Biotechnology.

[19]  A Caflisch,et al.  An evolutionary approach for structure-based design of natural and non-natural peptidic ligands. , 2001, Combinatorial chemistry & high throughput screening.

[20]  P. Schuster,et al.  Chance and necessity in evolution: lessons from RNA , 1998, physics/9811037.

[21]  W. F.,et al.  Shaping Space : the Possible and the Attainable in RNA Genotype – phenotype Mapping , 1997 .

[22]  Iosif I. Vaisman,et al.  Delaunay Tessellation of Proteins: Four Body Nearest-Neighbor Propensities of Amino Acid Residues , 1996, J. Comput. Biol..

[23]  L. Segel,et al.  Shape space: an approach to the evaluation of cross-reactivity effects, stability and controllability in the immune system. , 1989, Immunology letters.

[24]  John Maynard Smith,et al.  Natural Selection and the Concept of a Protein Space , 1970, Nature.

[25]  J. Maynard Smith.  Natural Selection and the Concept of a Protein Space , 1970 .